We went through the 50 like hot butter with 4 times average volume. Its clear to almost 5 dollars like you said at the twenty day. the 5 day chart looks great
This is a winner and a real target going into 2014. The great growth will be noticed. These clown shorts will be covering and crying. The industry will get even bigger and the money flow will wake the big players up.
It could be true. Big companies have to have an on going pipeline. These small Bio companies provide the returns for next year and 10 years to come. The Big Pharma stocks just came of a huge year with their market caps and money flow. 2014 they will be buying every thing in site. The support and financing could have been the deciding facture to make somebody put in a buy for the company. Pfizer could have decided they had to get it.
2014 A positive opinion by the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) for the continued availability of the company’s marketed drug Iclusig in the EU. ARIAD gained EU approval for Iclusig for a couple of indications in Jul 2013. Small investers are making a portfolio of top stocks at the rock-bottom prices today. In two years these small performers could be leaders in their particular field of studies. Many stocks flying this last month have been stars of the past that flew to early before results. Now results from studies are our and acceptance, partnering and commercialization is now a given. This is why every day a Pharmaceutical company has been up 30% daily. I see the cash flowing into the game changing new sciences. Life as we know it is defiantly changing for more patients as insurance is covering more procedures and patients. Some are playing the biotechnology micro caps for the take over as the pipeline in big pharma must be maintained. Others are chasing the record gains of the industry made last year in the bio fields. (1) European initiatives look very promising for Iclusig; this work will likely benefit very well both patients and the company; (2) uncertainty prevails in US over Iclusig return to market and differences between Ariad and FDA remain a very difficult barrier to surmount; (3) Clackson's public contesting of FDA change in methods of determination of adverse events was striking and hints at the level of disagreement, frustration, and anger among Ariad scientists and management with the FDA; (4) refocus of R&D on most promising candidates is encouraging, but sadly, limits innovation opportunities on other fronts; (5) interesting developments in Japan; (6) Europe, Uk, Germany , Australia sales – they reduced dose and took an asprin…… 600 DRs prescribed 1000 orders. ; (7) Narrowing business plan- cost cutting measures now in place are rightly based on most conservative financial outlook; terribly unfortunate for the company and its employees, but necessary part of this "crisis management" at this stage. 8) stock down 75% and upside out ways downside. 9) Stock could rocket with partner of FDA progress 9) breast cancer activity. 10) Marketing in 15 countries. 11) the company will be presenting some data at ASH that could help us clarify the risk/reward of ponatinib and possibly offer a chance at salvation for ARIAD Pharmaceuticals.